vs
Side-by-side financial comparison of Fidelity National Financial, Inc. (FNF) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $544.0M, roughly 1.9× Fidelity National Financial, Inc.). Hologic runs the higher net margin — 17.1% vs -21.5%, a 38.6% gap on every dollar of revenue. On growth, Fidelity National Financial, Inc. posted the faster year-over-year revenue change (10.3% vs 2.5%). Over the past eight quarters, Fidelity National Financial, Inc.'s revenue compounded faster (13.7% CAGR vs 1.5%).
Fidelity National Financial, Inc., is an American provider of title insurance and settlement services to the real estate and mortgage industries. A Fortune 500 company, Fidelity National Financial generated approximately $8.469 billion in annual revenue in 2019 from its title and real estate-related operations. The company was the first instance of an attorney licensed by a Native American Tribe being certified as "authorized house counsel" in the state of Florida.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
FNF vs HOLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $544.0M | $1.0B |
| Net Profit | $-117.0M | $179.1M |
| Gross Margin | — | 56.0% |
| Operating Margin | 82.9% | 22.6% |
| Net Margin | -21.5% | 17.1% |
| Revenue YoY | 10.3% | 2.5% |
| Net Profit YoY | -126.0% | -10.9% |
| EPS (diluted) | $-0.44 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $544.0M | $1.0B | ||
| Q3 25 | $553.0M | $1.0B | ||
| Q2 25 | $547.0M | $1.0B | ||
| Q1 25 | $455.0M | $1.0B | ||
| Q4 24 | $493.0M | $1.0B | ||
| Q3 24 | $506.0M | $988.0M | ||
| Q2 24 | $504.0M | $1.0B | ||
| Q1 24 | $421.0M | $1.0B |
| Q4 25 | $-117.0M | $179.1M | ||
| Q3 25 | $358.0M | $187.2M | ||
| Q2 25 | $278.0M | $194.9M | ||
| Q1 25 | $83.0M | $-17.4M | ||
| Q4 24 | $450.0M | $201.0M | ||
| Q3 24 | $266.0M | $178.6M | ||
| Q2 24 | $306.0M | $194.5M | ||
| Q1 24 | $248.0M | $169.9M |
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 55.6% | ||
| Q2 25 | — | 56.3% | ||
| Q1 25 | — | 37.5% | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 55.4% | ||
| Q1 24 | — | 53.3% |
| Q4 25 | 82.9% | 22.6% | ||
| Q3 25 | 81.9% | 22.6% | ||
| Q2 25 | 69.8% | 24.9% | ||
| Q1 25 | 24.4% | -0.7% | ||
| Q4 24 | — | 22.5% | ||
| Q3 24 | 61.9% | 23.3% | ||
| Q2 24 | 90.9% | 24.1% | ||
| Q1 24 | 78.6% | 20.7% |
| Q4 25 | -21.5% | 17.1% | ||
| Q3 25 | 64.7% | 17.8% | ||
| Q2 25 | 50.8% | 19.0% | ||
| Q1 25 | 18.2% | -1.7% | ||
| Q4 24 | 91.3% | 19.7% | ||
| Q3 24 | 52.6% | 18.1% | ||
| Q2 24 | 60.7% | 19.2% | ||
| Q1 24 | 58.9% | 16.7% |
| Q4 25 | $-0.44 | $0.79 | ||
| Q3 25 | $1.33 | $0.84 | ||
| Q2 25 | $1.02 | $0.86 | ||
| Q1 25 | $0.30 | $-0.08 | ||
| Q4 24 | $1.65 | $0.87 | ||
| Q3 24 | $0.97 | $0.75 | ||
| Q2 24 | $1.12 | $0.82 | ||
| Q1 24 | $0.91 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.6B | $2.4B |
| Total DebtLower is stronger | $4.4B | $2.5B |
| Stockholders' EquityBook value | $7.4B | $5.2B |
| Total Assets | $109.0B | $9.2B |
| Debt / EquityLower = less leverage | 0.59× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.6B | $2.4B | ||
| Q3 25 | $3.5B | $2.2B | ||
| Q2 25 | $3.3B | $1.9B | ||
| Q1 25 | $4.5B | $1.6B | ||
| Q4 24 | $3.5B | $2.0B | ||
| Q3 24 | $5.0B | $2.3B | ||
| Q2 24 | $4.9B | $2.4B | ||
| Q1 24 | $3.5B | $2.2B |
| Q4 25 | $4.4B | $2.5B | ||
| Q3 25 | $4.4B | $2.5B | ||
| Q2 25 | $4.4B | $2.5B | ||
| Q1 25 | $4.4B | $2.5B | ||
| Q4 24 | $4.3B | $2.5B | ||
| Q3 24 | $4.2B | $2.5B | ||
| Q2 24 | $4.2B | $2.5B | ||
| Q1 24 | $3.9B | $2.6B |
| Q4 25 | $7.4B | $5.2B | ||
| Q3 25 | $8.4B | $5.0B | ||
| Q2 25 | $7.9B | $4.8B | ||
| Q1 25 | $7.9B | $4.6B | ||
| Q4 24 | $7.8B | $4.8B | ||
| Q3 24 | $8.1B | $5.1B | ||
| Q2 24 | $7.3B | $5.0B | ||
| Q1 24 | $7.1B | $4.8B |
| Q4 25 | $109.0B | $9.2B | ||
| Q3 25 | $106.6B | $9.0B | ||
| Q2 25 | $102.3B | $8.8B | ||
| Q1 25 | $98.2B | $8.5B | ||
| Q4 24 | $95.4B | $8.7B | ||
| Q3 24 | $94.7B | $9.2B | ||
| Q2 24 | $88.8B | $8.9B | ||
| Q1 24 | $84.5B | $8.7B |
| Q4 25 | 0.59× | 0.48× | ||
| Q3 25 | 0.53× | 0.50× | ||
| Q2 25 | 0.56× | 0.52× | ||
| Q1 25 | 0.56× | 0.55× | ||
| Q4 24 | 0.56× | 0.53× | ||
| Q3 24 | 0.52× | 0.49× | ||
| Q2 24 | 0.58× | 0.51× | ||
| Q1 24 | 0.55× | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.5B | $229.9M |
| Free Cash FlowOCF − Capex | — | $215.2M |
| FCF MarginFCF / Revenue | — | 20.5% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.5B | $229.9M | ||
| Q3 25 | $1.3B | $355.1M | ||
| Q2 25 | $1.9B | $343.3M | ||
| Q1 25 | $1.1B | $169.4M | ||
| Q4 24 | $1.5B | $189.3M | ||
| Q3 24 | $2.4B | $367.0M | ||
| Q2 24 | $1.4B | $405.8M | ||
| Q1 24 | $1.6B | $292.4M |
| Q4 25 | — | $215.2M | ||
| Q3 25 | — | $341.4M | ||
| Q2 25 | — | $330.5M | ||
| Q1 25 | — | $153.9M | ||
| Q4 24 | — | $172.5M | ||
| Q3 24 | — | $350.6M | ||
| Q2 24 | — | $385.3M | ||
| Q1 24 | — | $279.6M |
| Q4 25 | — | 20.5% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 32.3% | ||
| Q1 25 | — | 15.3% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 35.5% | ||
| Q2 24 | — | 38.1% | ||
| Q1 24 | — | 27.5% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.3% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 1.3% |
| Q4 25 | — | 1.28× | ||
| Q3 25 | 3.66× | 1.90× | ||
| Q2 25 | 6.82× | 1.76× | ||
| Q1 25 | 13.43× | — | ||
| Q4 24 | 3.32× | 0.94× | ||
| Q3 24 | 8.89× | 2.05× | ||
| Q2 24 | 4.45× | 2.09× | ||
| Q1 24 | 6.42× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FNF
| Escrow Fees | $241.0M | 44% |
| Other Title Related Fees And Income | $182.0M | 33% |
| Service Link Excluding Title Premiums Escrow Fees And Subservicing Fees | $87.0M | 16% |
| Insurance Contracts Home Warranty | $31.0M | 6% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
